China approves Shanghai Fosun's unit to run human testing for BioNTech's Covid-19 vaccine

The experimental Covid-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech's partner Pfizer Inc said on Monday